{"ticker": {"uuid": "baef9e23-7147-4b54-8d85-2b08d0d1f9e8", "symbol": "PASG", "name": "Passage Bio Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Passage Bio eyes gene therapy progress as Nasdaq-listed biotech develops CNS pipeline", "summary": "Passage Bio Inc. (PASG) is a Nasdaq-listed, clinical-stage genetic medicines company focused on developing gene therapies for rare, monogenic central nervous system disorders. The company leverages an adeno-associated virus-based gene therapy platform and strong academic connecti", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/passage-bio-eyes-gene-therapy-progress-as-nasdaq-listed-biotech-develops/69723648", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T12:10:40", "published_display": "08 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio focuses on genetic medicine strategy as investors weigh long-term potential", "summary": "Passage Bio Inc. is a clinical-stage genetic medicines company developing gene therapies for rare neurological disorders. The company's strategy involves using adeno-associated virus vectors to correct underlying genetic defects, focusing on clinical progress and regulatory miles", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/passage-bio-focuses-on-genetic-medicine-strategy-as-investors-weigh/69716439", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T17:44:54", "published_display": "07 Jul 2026 17:44", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio, Inc. Financial Disclosures & SEC Filings", "summary": "This article provides a comprehensive list of Passage Bio, Inc.'s financial disclosures and SEC filings, including earnings reports, corporate presentations, and annual meetings, spanning from 2024 to mid-2026. It highlights key events such as M&A announcements, clinical trial pr", "url": "https://www.tradingview.com/symbols/BOATS-PASG/documents/", "source_name": "TradingView", "published_at": "2026-07-03T18:10:52", "published_display": "03 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio explores gene therapy potential as investors weigh long-term prospects", "summary": "Passage Bio Inc. is a clinical-stage genetic medicine company focused on developing gene therapies for rare neurological disorders, representing a speculative, long-term innovation play for investors. The company's strategy involves advancing candidates through preclinical and ea", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/passage-bio-explores-gene-therapy-potential-as-investors-weigh-long-term/69681367", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T16:10:08", "published_display": "03 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage BIO (NASDAQ: PASG) holder Lynx1 reports 21% ownership amid Remix deal", "summary": "Lynx1 Capital Management has disclosed a 21% stake in Passage BIO (NASDAQ: PASG) through a Schedule 13D filing, indicating its belief that the stock is undervalued. The filing comes as Passage BIO plans to merge with Remix Therapeutics, with Lynx1 agreeing to participate in a con", "url": "https://www.stocktitan.net/sec-filings/PASG/schedule-13d-passage-bio-inc-major-shareholder-acquisition-5-9e167e899ac3.html", "source_name": "Stock Titan", "published_at": "2026-07-03T07:10:21", "published_display": "03 Jul 2026 07:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lynx1 Capital Management Discloses Investment at Passage BIO with 21.0% Stake", "summary": "Lynx1 Capital Management LP has disclosed a 21.0% stake in Passage BIO, Inc., filing a Schedule 13D after its ownership crossed 20%, indicating a more active investment approach. This move is tied to Passage BIO's merger with Remix Therapeutics, with Lynx1 agreeing to participate", "url": "https://www.tradingview.com/news/tradingview:d90fb68fa320e:0-lynx1-capital-management-discloses-investment-at-passage-bio-with-21-0-stake/", "source_name": "TradingView", "published_at": "2026-07-03T01:09:11", "published_display": "03 Jul 2026 01:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PASG - Passage Bio Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and a comprehensive financial overview for Passage Bio Inc (PASG). It details key financial metrics, stock performance data, insider and institutional ownership, and analyst recommendations. The company's last close was $4.68, with a m", "url": "https://finviz.com/stock?t=PASG&p=w&ty=lf&b=2&r=y2&page=15", "source_name": "Finviz", "published_at": "2026-07-02T17:10:08", "published_display": "02 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio (PASG) holder adds 50,055 shares in open-market buy", "summary": "Lynx1 Master Fund LP, associated with Lynx1 Capital Management LP and Weston Nichols, purchased 50,055 shares of Passage Bio's common stock in an open-market transaction. The shares were bought at a weighted average price of $4.1175, ranging from $3.33 to $4.30 per share. Followi", "url": "https://www.stocktitan.net/sec-filings/PASG/form-4-passage-bio-inc-insider-trading-activity-8cf7f86d1d5a.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:40:35", "published_display": "29 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Passage Bio, Inc. \u2013 NASDAQ:PASG", "summary": "This article displays the \"Price to book forward\" metric for Passage Bio, Inc. (NASDAQ: PASG) on the TradingView platform. It presents this financial data point within the context of the company's overall financial information on the site.", "url": "https://www.tradingview.com/symbols/NASDAQ-PASG/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T14:10:00", "published_display": "26 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio, Inc. Actuals & Estimates (NASDAQ:PASG)", "summary": "This article provides an overview of Passage Bio, Inc. (NASDAQ:PASG) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights key metrics such as market capitalization, volatility, and details from recent earnings reports, n", "url": "https://www.tradingview.com/symbols/NASDAQ-PASG/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T10:09:45", "published_display": "26 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Passage Bio, Inc. \u2013 NASDAQ:PASG", "summary": "This article provides financial information for Passage Bio, Inc. (NASDAQ: PASG), specifically detailing its enterprise value to EBIT forward. It is presented on the TradingView platform, which offers various market data and analysis tools for stocks, ETFs, bonds, and cryptocurre", "url": "https://www.tradingview.com/symbols/NASDAQ-PASG/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T09:09:45", "published_display": "26 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Latham & Watkins Advises Remix Therapeutics in Merger With Passage Bio", "summary": "Latham & Watkins LLP advised Remix Therapeutics in its definitive merger agreement with Passage Bio. The all-stock transaction will result in the combined company operating as Remix Therapeutics, Inc., trading on Nasdaq under the ticker symbol RMTX. The multidisciplinary legal te", "url": "https://www.lw.com/en/news/2026/06/latham-watkins-advises-remix-therapeutics-in-merger-with-passage-bio", "source_name": "Latham & Watkins LLP", "published_at": "2026-06-26T06:41:24", "published_display": "26 Jun 2026 06:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Passage Bio, Inc. \u2013 NASDAQ:PASG", "summary": "This article provides the \"Price to sales forward\" metric for Passage Bio, Inc. (NASDAQ: PASG). It appears to be a financial data point from TradingView, focusing on investment analysis for the biotechnology company. The content primarily lists navigation and data source acknowle", "url": "https://www.tradingview.com/symbols/NASDAQ-PASG/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T05:41:24", "published_display": "26 Jun 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Baselake Partners (PASG) reports 235,058 shares, 7.3% ownership", "summary": "Baselake Partners, LP, along with Baselake Management, LLC and David Paolella, has reported a 7.3% ownership stake in Passage Bio, Inc. (PASG) through a Schedule 13G SEC filing. This amounts to 235,058 shares, based on Passage Bio's 3,207,810 shares outstanding as of May 7, 2026.", "url": "https://www.stocktitan.net/sec-filings/PASG/schedule-13g-passage-bio-inc-passive-investment-disclosure-5-8730b63bc438.html", "source_name": "Stock Titan", "published_at": "2026-06-25T22:40:43", "published_display": "25 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio And Remix Therapeutics Announce Merger Agreement", "summary": "Passage Bio and Remix Therapeutics have announced a merger agreement. This news was reported by Refinitiv via Reuters. The full details of the agreement are available through signing in or creating a free account on the platform.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_TUAPGNKQ:0-passage-bio-and-remix-therapeutics-announce-merger-agreement/", "source_name": "TradingView", "published_at": "2026-06-25T22:10:38", "published_display": "25 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio to Merge With Remix Therapeutics; Remix Valued at $226M, $100M Financing", "summary": "Passage Bio has signed a definitive merger agreement to acquire Remix Therapeutics in a stock-for-stock deal, valuing Remix at $226 million and Passage Bio at approximately $20 million. The merger includes a concurrent financing of at least $100 million for Remix and will result ", "url": "https://www.tradingview.com/news/tradingview:45c070dcb1e05:0-passage-bio-to-merge-with-remix-therapeutics-remix-valued-at-226m-100m-financing/", "source_name": "TradingView", "published_at": "2026-06-25T20:10:38", "published_display": "25 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Remix Therapeutics secures $100M and a reverse merger", "summary": "Remix Therapeutics has announced a successful $100 million private placement financing round, led by Decheng Capital. This funding is part of a reverse merger deal with Passage Bio. The article highlights this significant financial move for Remix Therapeutics.", "url": "https://www.bizjournals.com/boston/news/2026/06/25/remix-therapeutics-reverse-merger.html", "source_name": "The Business Journals", "published_at": "2026-06-25T17:40:43", "published_display": "25 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Remix to go public in reverse merger with once high-flying Passage Bio", "summary": "Remix Therapeutics is set to go public through a reverse merger with Passage Bio, a gene therapy company that has seen its stock price fall significantly. The deal, expected to close in the fourth quarter, will result in Remix investors owning about 93% of the new entity, which w", "url": "https://www.biopharmadive.com/news/passage-bio-remix-reverse-merger-gene-therapy-wilson/823775/", "source_name": "BioPharma Dive", "published_at": "2026-06-25T16:40:43", "published_display": "25 Jun 2026 16:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Passage Bio and Remix Therapeutics Announce Merger Agreement", "summary": "Passage Bio and Remix Therapeutics have announced a definitive merger agreement, under which Remix will merge with a wholly-owned subsidiary of Passage Bio. The combined company will focus on advancing Remix Therapeutics' pipeline of small molecule therapeutics that modulate RNA ", "url": "https://www.moomoo.com/news/post/71984106/press-release-passage-bio-and-remix-therapeutics-announce-merger-agreement", "source_name": "Moomoo", "published_at": "2026-06-25T16:10:06", "published_display": "25 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PASG Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Passage Bio, Inc. (PASG) stock, drawing on analyst opinions. It includes current stock performance metrics, historical highs and lows, volatility, market capitalization, and details on recent earnings and revenue. The article ", "url": "https://www.tradingview.com/symbols/NASDAQ-PASG/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T13:40:43", "published_display": "25 Jun 2026 13:40", "sentiment": "negative", "sentiment_pct": 35, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Remix to enter Nasdaq through Passage Bio reverse merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQLUwwUUdkemxNNHNieEVPVzNqS3hHTlBSc1RJaF9mVFkweWVmc0huOHhGaDRtYmw1ai1OelU5OGJCV2xUbllESTFlMG8zTzhYRUN3OGNoajl4eEJrOVdseGtDaHdyNW5tYUxUdTFHendjTXFYUWNUaENESTVCRmJFQXFjVWdYUk8wTE1NYkpHU0tYd0tmSkMxUkJHem9tYzZIYWJR?oc=5", "source_name": "The Pharma Letter", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio (PASG) to merge with Remix; Remix private placement tops $100M", "summary": "Passage Bio (PASG) announced a definitive merger agreement with Remix Therapeutics and a concurrent private placement exceeding $100 million. Post-merger, Passage Bio shareholders will own approximately 7% of the combined company, and Remix shareholders will own 93%. The combined", "url": "https://www.stocktitan.net/sec-filings/PASG/425-passage-bio-inc-business-combination-communication-3079b48ff856.html", "source_name": "Stock Titan", "published_at": "2026-06-25T01:10:38", "published_display": "25 Jun 2026 01:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio (PASG) to combine with Remix; Remix valued at $226M, $100M raise", "summary": "Passage Bio, Inc. has entered into a definitive merger agreement with Remix Therapeutics, Inc. The deal values Remix at $226 million and Passage Bio at approximately $20 million, with a planned Concurrent Financing of at least $100 million for Remix prior to closing. The combined", "url": "https://www.stocktitan.net/sec-filings/PASG/425-passage-bio-inc-business-combination-communication-274006dec513.html", "source_name": "Stock Titan", "published_at": "2026-06-25T00:10:38", "published_display": "25 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio, Remix Therapeutics Plan All-Stock Merger", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/passage-bio-remix-therapeutics-plan-210438270.html", "source_name": "MT Newswires", "published_at": "2026-06-24T21:04:38+00:00", "published_display": "24 Jun 2026 21:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Remix Therapeutics to reverse-merge with Passage Bio (PASG) and raise $100M", "summary": "Passage Bio (PASG) has entered into a definitive all-stock merger agreement with Remix Therapeutics, Inc., a clinical-stage biotech company. The deal will result in pre-merger Passage Bio shareholders owning about 7% of the combined company and Remix holders about 93%, with Remix", "url": "https://www.stocktitan.net/sec-filings/PASG/8-k-passage-bio-inc-reports-material-event-a99395a34991.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:10:38", "published_display": "24 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spurned by the FDA, Passage Bio finds an exit through Remix", "summary": "Passage Bio, a gene therapy company, has entered an all-stock reverse merger with RNA specialist Remix Therapeutics after facing FDA disapproval for its lead candidate and undergoing a strategic review. The combined company will operate under the Remix name, with Passage Bio shar", "url": "https://www.fiercebiotech.com/biotech/spurned-fda-passage-bio-finds-exit-through-merger-remix", "source_name": "Fierce Biotech", "published_at": "2026-06-24T17:20:00", "published_display": "24 Jun 2026 17:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio to merge with Remix Therapeutics in all-stock deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNUTNRZFVWVUtQSlY3dE9QRnh6Rmp0ZFhTTkxmSW84M1pRcExfU09SUkNFU0hLQmx5Y19oMFJUcXg0NWRyNVZFMF9weldjUDEtUXhLVXg2MU9sX0lBLUxHbGt1RENHeHNKMXdSVjFZWFRzSGFIWUliYlZtRXVSdzJDOUcxV09nejFtZ05UdmtlMk5XLXVaR3pXZHZ3RDZpbjFObk8tNXExQlFhZ0VrN3ZTM2pURlc0cjM0ZWc?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio and Remix merge with $100M to fund clinical readouts into 2028", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPSzg4XzhNQ0NWRHUzcndMa2NEZW5oS0xTckl3RWgyc05RWGNmXzNsOHZ5TEtHdDB4ME0zVllMQXl0bVJmQlM5T0hodjJNQk1MMUczaGx6aGZxLTNFLTk1QTdBcEJ1WEIzZkdlNjFnYjBQUnVodGQzdW1aejRBQVZ3WE10SV9aNWplRExEQ3FKemRoOTZRaURHMTM5N1l4NWNaNXhPUEJSYUc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio Inc (PASG) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Passage Bio Inc (PASG), detailing analyst ratings, price targets, and EPS expectations. Based on 4 analysts, the current rating is \"Hold\" with a target price of USD 53.50, suggesting a significant upside. The report highlights past E", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pasg/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T20:10:40", "published_display": "17 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio Inc (PASG) Institutional Confidence", "summary": "This article provides details on Passage Bio Inc (PASG) stock, focusing on its institutional confidence and shareholder activity. It lists key institutional holders, their share counts, and recent changes in their holdings, such as increases by Renaissance Technologies LLC and Ge", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pasg/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T20:10:40", "published_display": "17 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim Downgrades Passage Bio(PASG.US) to Hold Rating", "summary": "Guggenheim has downgraded Passage Bio (PASG.US) from a \"Buy\" rating to a \"Hold\" rating. This change reflects a revised outlook from the investment firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/71330038/guggenheim-downgrades-passage-bio-pasgus-to-hold-rating", "source_name": "Moomoo", "published_at": "2026-06-10T17:40:05", "published_display": "10 Jun 2026 17:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio (PASG) Downgraded to Neutral as Strategic Review Initiated", "summary": "Guggenheim analyst Debjit Chattopadhyay has downgraded Passage Bio (PASG) from \"Buy\" to \"Neutral\" and ceased coverage, citing uncertainties as the company begins a strategic review to enhance shareholder value, potentially through mergers or acquisitions. Passage Bio, a biotechno", "url": "https://www.gurufocus.com/news/8909636/passage-bio-pasg-downgraded-to-neutral-as-strategic-review-initiated", "source_name": "GuruFocus", "published_at": "2026-06-10T12:10:29", "published_display": "10 Jun 2026 12:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNZl9acG9NWk9ldHEwbkhUQUwwSjVQV0pycVVGald1cDM4ZDlxVGgwejhpTzc0VVdWc1U3R2xISkY3OWUtX1lBRWR2bFk5amxhN2VuZWtTYVRxcWsyUnN1SzM2WmN5QU55dEFzQjVjRUxfM2xhUUI0S241YXhPMFhYVVhSNVFaemV6SkM0dkludXp5d0J6NFE?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio to cut its workforce to the bone, laying off 75% of remaining employees", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPMGkwdEl1Yk9tckVqYkVKeUgwVzFra2hYc3BHV2EyeU5QTXFXbTY1UmlkZVBEQTUzSkt0NFdWSEUzSG5MT0tGQ29yS0U0cjZJekJRSEY2UzNzbzVnX0twekl5N241SnRNSERBa0FfSm1tRzYyRFVqU1c0dFNyNXQ3cmZnMS0td3NlRWxCM1pUX2ozalpwMk9ReG9ZQUhsNmlVM3dxeEozd2lZYUU?oc=5", "source_name": "The Business Journals", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Passage Bio Shares Latest Interim Data from UpliFT-D Clinical Trial - AFTD", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTFB1U1BHcVJzYmlFOVJQcFRKU0lVTjZWMGxuRFNLeXJiMzZtWmZqTjVmeXdtME1ycHdWMEdPTzNoTzNoNEl2Yjd6cGtpZzRwNGR5N0ZvN3FzZDRGdG5fRWNMOW9tdHh2Q24zQ1ltSjU5YVRFX2wza3hHaDdBQURqZw?oc=5", "source_name": "The Association for Frontotemporal Degeneration", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Says", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/passage-bio-faces-tougher-fda-182044884.html", "source_name": "MT Newswires", "published_at": "2026-04-21T18:20:44+00:00", "published_display": "21 Apr 2026 18:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "FDA wants a controlled trial even as Passage Bio posts biomarker gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNZHRMZkR0MjRESzVtODBOZ3QxUjlNYjRVbzVza2NsVmJkUklOcTBXT29xUHJwQ1ZkNHVBZEZPSVFJbVQ5S09fZGdoc2lqajVpRzQxSjFfWkxuelR5NDlBQW1BWTF4b1J1eklhWW9Za0J3WFROU0c1bGRFaEJyNzI4d0c5bUNIemlmX2RBd0t2MEhsNk5iUFp1aTNEd1dKc1E2VEViM2otbGtmcVkxV0pDR0hFbkN1NTVGVldDRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxNeWxEN3Excm1oajE3M2hKUVFPdTZ4YWQzSEVIbTRLWU5XZzFUM2U4dFVPTXIwUFpUQ2dYUEFNV1BVOHdBOW5kVUtDMUJFNjc5YlNDeXRrSEt2MnUyVEtkWmEwZHBYdUxialExdmFlblpyYk13ZmszTF9UaU4wN2pZS0ZKVUpUMFJsVXB6VWJDYmlMdWctNEd2bGhsQU43WlV5MF91YVQxUDAwaTR2UUJsbkNKdmh6RFRFNlM3aGp3V21jRThVTzZvRDlPOUVxOEZwYTNIb3l3U0Fva2F0d1JGNWhjNHpMbEZBV2Jvc0x2TFpVX3hsQ09oNm1lbTV1Zy1NdmFtVzBRRzBzZw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio reports biomarker improvements in FTD trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQVWhOVHVEUFplVVNVbUNMdmszX2ZrVUF4WXJiRzNtallXM2pqNF82djJBMXVUUXU0dlpUNFdQS3JpRzltN1lkNkgybVFqVFhRZWhheGZ6Ri1QSy0yU0lkLU5YRVVsYWpzRUJLUXBFX1pVQlozZ18xc1AtUklHd3k5NDctNUg0eUl1Y2wzMldOSDFQckpISjJWcGhidXIxQ0xxU2lsUGRkX0dKaGhvVi0wdHZ3?oc=5", "source_name": "Investing.com", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxNMVRFZDhZMWoyWTBaU2xhbXBjbzFUVUJ3SHdkZ0tWUkdrdVRVcUJoREFvNm9sUGVBZ1ZBTGtSeHctbE9oZGc3ZmFUU1dYc283a3lMby0tR3lTdmdzc0dSQ2NNSHRLeXJjZjBlbElnRE0tcVJidE9Idl9mRGxoU3plRHJSaThaMkY1Q0p1ZHMtTzNubmlXZTQtemxaQ3lXUXNrdUo0bzF2ZEp5amk3cHNkOGNQVnRYQUVrSFVJdXFmbkpRR29UQzVzOHgyXy1DYVJvcXlCbGwyeGJ3REUzOEJxeWI2bWozaUlydWltRHpiVW5DNF9JbTliUW80dU42UE5hc01jTkIzajFvVU14bjN5Vg?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Passage Bio (PASG)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE83cC1FZ0VId1U3VmRqbEhFa3BwVHk2bjhjeG5WeUFzWGlnbmhPUTVZdWdNT0JrUDktYXpRVEJKTDVYQzNQVE1WQWMxOEtabWJOT1BkOWZub0xtTnoycVI2NnBZYnJvLUlqSUJ0aA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2025-08-15T07:00:00+00:00", "published_display": "15 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio\u2019s Dementia Gene Therapy Trial Expands Patient Pool", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPYkY1dmtYQkw0M2pCYWlKX3ljX1ppNU9FM3R4VktVMXFKc3huNHlaekZDSmdfTlNpSEZkeDZzdUt6RkdBbzNZNjBLOGNVVnFNN2k0OVBZTjdBV0xHVDl0dTJrX05TNDNhWnFObmplWDFhS3AzSFNDZ2x3N0FGa3BVb2lLVkZKcC1QdzRRS2hwclVTZzl3Q3dSLUlNdnlGU1VhWXZjTk9nYXIydFd3MHJRVGY0VnF1UjdjUTZQZm5FWDcyMXkwYjNN?oc=5", "source_name": "Inside Precision Medicine", "published_at": "2024-07-17T07:00:00+00:00", "published_display": "17 Jul 2024 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Passage Bio eyes gene therapy progress as Nasdaq-listed biotech develops CNS pipeline", "summary": "Passage Bio Inc. (PASG) is a Nasdaq-listed, clinical-stage genetic medicines company focused on developing gene therapies for rare, monogenic central nervous system disorders. The company leverages an adeno-associated virus-based gene therapy platform and strong academic connecti", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/passage-bio-eyes-gene-therapy-progress-as-nasdaq-listed-biotech-develops/69723648", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T12:10:40", "published_display": "08 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio focuses on genetic medicine strategy as investors weigh long-term potential", "summary": "Passage Bio Inc. is a clinical-stage genetic medicines company developing gene therapies for rare neurological disorders. The company's strategy involves using adeno-associated virus vectors to correct underlying genetic defects, focusing on clinical progress and regulatory miles", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/passage-bio-focuses-on-genetic-medicine-strategy-as-investors-weigh/69716439", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T17:44:54", "published_display": "07 Jul 2026 17:44", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio, Inc. Financial Disclosures & SEC Filings", "summary": "This article provides a comprehensive list of Passage Bio, Inc.'s financial disclosures and SEC filings, including earnings reports, corporate presentations, and annual meetings, spanning from 2024 to mid-2026. It highlights key events such as M&A announcements, clinical trial pr", "url": "https://www.tradingview.com/symbols/BOATS-PASG/documents/", "source_name": "TradingView", "published_at": "2026-07-03T18:10:52", "published_display": "03 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio explores gene therapy potential as investors weigh long-term prospects", "summary": "Passage Bio Inc. is a clinical-stage genetic medicine company focused on developing gene therapies for rare neurological disorders, representing a speculative, long-term innovation play for investors. The company's strategy involves advancing candidates through preclinical and ea", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/passage-bio-explores-gene-therapy-potential-as-investors-weigh-long-term/69681367", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T16:10:08", "published_display": "03 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage BIO (NASDAQ: PASG) holder Lynx1 reports 21% ownership amid Remix deal", "summary": "Lynx1 Capital Management has disclosed a 21% stake in Passage BIO (NASDAQ: PASG) through a Schedule 13D filing, indicating its belief that the stock is undervalued. The filing comes as Passage BIO plans to merge with Remix Therapeutics, with Lynx1 agreeing to participate in a con", "url": "https://www.stocktitan.net/sec-filings/PASG/schedule-13d-passage-bio-inc-major-shareholder-acquisition-5-9e167e899ac3.html", "source_name": "Stock Titan", "published_at": "2026-07-03T07:10:21", "published_display": "03 Jul 2026 07:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lynx1 Capital Management Discloses Investment at Passage BIO with 21.0% Stake", "summary": "Lynx1 Capital Management LP has disclosed a 21.0% stake in Passage BIO, Inc., filing a Schedule 13D after its ownership crossed 20%, indicating a more active investment approach. This move is tied to Passage BIO's merger with Remix Therapeutics, with Lynx1 agreeing to participate", "url": "https://www.tradingview.com/news/tradingview:d90fb68fa320e:0-lynx1-capital-management-discloses-investment-at-passage-bio-with-21-0-stake/", "source_name": "TradingView", "published_at": "2026-07-03T01:09:11", "published_display": "03 Jul 2026 01:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PASG - Passage Bio Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and a comprehensive financial overview for Passage Bio Inc (PASG). It details key financial metrics, stock performance data, insider and institutional ownership, and analyst recommendations. The company's last close was $4.68, with a m", "url": "https://finviz.com/stock?t=PASG&p=w&ty=lf&b=2&r=y2&page=15", "source_name": "Finviz", "published_at": "2026-07-02T17:10:08", "published_display": "02 Jul 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio (PASG) holder adds 50,055 shares in open-market buy", "summary": "Lynx1 Master Fund LP, associated with Lynx1 Capital Management LP and Weston Nichols, purchased 50,055 shares of Passage Bio's common stock in an open-market transaction. The shares were bought at a weighted average price of $4.1175, ranging from $3.33 to $4.30 per share. Followi", "url": "https://www.stocktitan.net/sec-filings/PASG/form-4-passage-bio-inc-insider-trading-activity-8cf7f86d1d5a.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:40:35", "published_display": "29 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Passage Bio, Inc. \u2013 NASDAQ:PASG", "summary": "This article displays the \"Price to book forward\" metric for Passage Bio, Inc. (NASDAQ: PASG) on the TradingView platform. It presents this financial data point within the context of the company's overall financial information on the site.", "url": "https://www.tradingview.com/symbols/NASDAQ-PASG/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T14:10:00", "published_display": "26 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio, Inc. Actuals & Estimates (NASDAQ:PASG)", "summary": "This article provides an overview of Passage Bio, Inc. (NASDAQ:PASG) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights key metrics such as market capitalization, volatility, and details from recent earnings reports, n", "url": "https://www.tradingview.com/symbols/NASDAQ-PASG/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T10:09:45", "published_display": "26 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Passage Bio, Inc. \u2013 NASDAQ:PASG", "summary": "This article provides financial information for Passage Bio, Inc. (NASDAQ: PASG), specifically detailing its enterprise value to EBIT forward. It is presented on the TradingView platform, which offers various market data and analysis tools for stocks, ETFs, bonds, and cryptocurre", "url": "https://www.tradingview.com/symbols/NASDAQ-PASG/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T09:09:45", "published_display": "26 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Latham & Watkins Advises Remix Therapeutics in Merger With Passage Bio", "summary": "Latham & Watkins LLP advised Remix Therapeutics in its definitive merger agreement with Passage Bio. The all-stock transaction will result in the combined company operating as Remix Therapeutics, Inc., trading on Nasdaq under the ticker symbol RMTX. The multidisciplinary legal te", "url": "https://www.lw.com/en/news/2026/06/latham-watkins-advises-remix-therapeutics-in-merger-with-passage-bio", "source_name": "Latham & Watkins LLP", "published_at": "2026-06-26T06:41:24", "published_display": "26 Jun 2026 06:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Passage Bio, Inc. \u2013 NASDAQ:PASG", "summary": "This article provides the \"Price to sales forward\" metric for Passage Bio, Inc. (NASDAQ: PASG). It appears to be a financial data point from TradingView, focusing on investment analysis for the biotechnology company. The content primarily lists navigation and data source acknowle", "url": "https://www.tradingview.com/symbols/NASDAQ-PASG/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T05:41:24", "published_display": "26 Jun 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Baselake Partners (PASG) reports 235,058 shares, 7.3% ownership", "summary": "Baselake Partners, LP, along with Baselake Management, LLC and David Paolella, has reported a 7.3% ownership stake in Passage Bio, Inc. (PASG) through a Schedule 13G SEC filing. This amounts to 235,058 shares, based on Passage Bio's 3,207,810 shares outstanding as of May 7, 2026.", "url": "https://www.stocktitan.net/sec-filings/PASG/schedule-13g-passage-bio-inc-passive-investment-disclosure-5-8730b63bc438.html", "source_name": "Stock Titan", "published_at": "2026-06-25T22:40:43", "published_display": "25 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio And Remix Therapeutics Announce Merger Agreement", "summary": "Passage Bio and Remix Therapeutics have announced a merger agreement. This news was reported by Refinitiv via Reuters. The full details of the agreement are available through signing in or creating a free account on the platform.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_TUAPGNKQ:0-passage-bio-and-remix-therapeutics-announce-merger-agreement/", "source_name": "TradingView", "published_at": "2026-06-25T22:10:38", "published_display": "25 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio to Merge With Remix Therapeutics; Remix Valued at $226M, $100M Financing", "summary": "Passage Bio has signed a definitive merger agreement to acquire Remix Therapeutics in a stock-for-stock deal, valuing Remix at $226 million and Passage Bio at approximately $20 million. The merger includes a concurrent financing of at least $100 million for Remix and will result ", "url": "https://www.tradingview.com/news/tradingview:45c070dcb1e05:0-passage-bio-to-merge-with-remix-therapeutics-remix-valued-at-226m-100m-financing/", "source_name": "TradingView", "published_at": "2026-06-25T20:10:38", "published_display": "25 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Remix Therapeutics secures $100M and a reverse merger", "summary": "Remix Therapeutics has announced a successful $100 million private placement financing round, led by Decheng Capital. This funding is part of a reverse merger deal with Passage Bio. The article highlights this significant financial move for Remix Therapeutics.", "url": "https://www.bizjournals.com/boston/news/2026/06/25/remix-therapeutics-reverse-merger.html", "source_name": "The Business Journals", "published_at": "2026-06-25T17:40:43", "published_display": "25 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Remix to go public in reverse merger with once high-flying Passage Bio", "summary": "Remix Therapeutics is set to go public through a reverse merger with Passage Bio, a gene therapy company that has seen its stock price fall significantly. The deal, expected to close in the fourth quarter, will result in Remix investors owning about 93% of the new entity, which w", "url": "https://www.biopharmadive.com/news/passage-bio-remix-reverse-merger-gene-therapy-wilson/823775/", "source_name": "BioPharma Dive", "published_at": "2026-06-25T16:40:43", "published_display": "25 Jun 2026 16:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Passage Bio and Remix Therapeutics Announce Merger Agreement", "summary": "Passage Bio and Remix Therapeutics have announced a definitive merger agreement, under which Remix will merge with a wholly-owned subsidiary of Passage Bio. The combined company will focus on advancing Remix Therapeutics' pipeline of small molecule therapeutics that modulate RNA ", "url": "https://www.moomoo.com/news/post/71984106/press-release-passage-bio-and-remix-therapeutics-announce-merger-agreement", "source_name": "Moomoo", "published_at": "2026-06-25T16:10:06", "published_display": "25 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PASG Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Passage Bio, Inc. (PASG) stock, drawing on analyst opinions. It includes current stock performance metrics, historical highs and lows, volatility, market capitalization, and details on recent earnings and revenue. The article ", "url": "https://www.tradingview.com/symbols/NASDAQ-PASG/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T13:40:43", "published_display": "25 Jun 2026 13:40", "sentiment": "negative", "sentiment_pct": 35, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Remix to enter Nasdaq through Passage Bio reverse merger", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQLUwwUUdkemxNNHNieEVPVzNqS3hHTlBSc1RJaF9mVFkweWVmc0huOHhGaDRtYmw1ai1OelU5OGJCV2xUbllESTFlMG8zTzhYRUN3OGNoajl4eEJrOVdseGtDaHdyNW5tYUxUdTFHendjTXFYUWNUaENESTVCRmJFQXFjVWdYUk8wTE1NYkpHU0tYd0tmSkMxUkJHem9tYzZIYWJR?oc=5", "source_name": "The Pharma Letter", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio (PASG) to merge with Remix; Remix private placement tops $100M", "summary": "Passage Bio (PASG) announced a definitive merger agreement with Remix Therapeutics and a concurrent private placement exceeding $100 million. Post-merger, Passage Bio shareholders will own approximately 7% of the combined company, and Remix shareholders will own 93%. The combined", "url": "https://www.stocktitan.net/sec-filings/PASG/425-passage-bio-inc-business-combination-communication-3079b48ff856.html", "source_name": "Stock Titan", "published_at": "2026-06-25T01:10:38", "published_display": "25 Jun 2026 01:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio (PASG) to combine with Remix; Remix valued at $226M, $100M raise", "summary": "Passage Bio, Inc. has entered into a definitive merger agreement with Remix Therapeutics, Inc. The deal values Remix at $226 million and Passage Bio at approximately $20 million, with a planned Concurrent Financing of at least $100 million for Remix prior to closing. The combined", "url": "https://www.stocktitan.net/sec-filings/PASG/425-passage-bio-inc-business-combination-communication-274006dec513.html", "source_name": "Stock Titan", "published_at": "2026-06-25T00:10:38", "published_display": "25 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio, Remix Therapeutics Plan All-Stock Merger", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/passage-bio-remix-therapeutics-plan-210438270.html", "source_name": "MT Newswires", "published_at": "2026-06-24T21:04:38+00:00", "published_display": "24 Jun 2026 21:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Remix Therapeutics to reverse-merge with Passage Bio (PASG) and raise $100M", "summary": "Passage Bio (PASG) has entered into a definitive all-stock merger agreement with Remix Therapeutics, Inc., a clinical-stage biotech company. The deal will result in pre-merger Passage Bio shareholders owning about 7% of the combined company and Remix holders about 93%, with Remix", "url": "https://www.stocktitan.net/sec-filings/PASG/8-k-passage-bio-inc-reports-material-event-a99395a34991.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:10:38", "published_display": "24 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spurned by the FDA, Passage Bio finds an exit through Remix", "summary": "Passage Bio, a gene therapy company, has entered an all-stock reverse merger with RNA specialist Remix Therapeutics after facing FDA disapproval for its lead candidate and undergoing a strategic review. The combined company will operate under the Remix name, with Passage Bio shar", "url": "https://www.fiercebiotech.com/biotech/spurned-fda-passage-bio-finds-exit-through-merger-remix", "source_name": "Fierce Biotech", "published_at": "2026-06-24T17:20:00", "published_display": "24 Jun 2026 17:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio to merge with Remix Therapeutics in all-stock deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNUTNRZFVWVUtQSlY3dE9QRnh6Rmp0ZFhTTkxmSW84M1pRcExfU09SUkNFU0hLQmx5Y19oMFJUcXg0NWRyNVZFMF9weldjUDEtUXhLVXg2MU9sX0lBLUxHbGt1RENHeHNKMXdSVjFZWFRzSGFIWUliYlZtRXVSdzJDOUcxV09nejFtZ05UdmtlMk5XLXVaR3pXZHZ3RDZpbjFObk8tNXExQlFhZ0VrN3ZTM2pURlc0cjM0ZWc?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio and Remix merge with $100M to fund clinical readouts into 2028", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPSzg4XzhNQ0NWRHUzcndMa2NEZW5oS0xTckl3RWgyc05RWGNmXzNsOHZ5TEtHdDB4ME0zVllMQXl0bVJmQlM5T0hodjJNQk1MMUczaGx6aGZxLTNFLTk1QTdBcEJ1WEIzZkdlNjFnYjBQUnVodGQzdW1aejRBQVZ3WE10SV9aNWplRExEQ3FKemRoOTZRaURHMTM5N1l4NWNaNXhPUEJSYUc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio Inc (PASG) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Passage Bio Inc (PASG), detailing analyst ratings, price targets, and EPS expectations. Based on 4 analysts, the current rating is \"Hold\" with a target price of USD 53.50, suggesting a significant upside. The report highlights past E", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pasg/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T20:10:40", "published_display": "17 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio Inc (PASG) Institutional Confidence", "summary": "This article provides details on Passage Bio Inc (PASG) stock, focusing on its institutional confidence and shareholder activity. It lists key institutional holders, their share counts, and recent changes in their holdings, such as increases by Renaissance Technologies LLC and Ge", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-pasg/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T20:10:40", "published_display": "17 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim Downgrades Passage Bio(PASG.US) to Hold Rating", "summary": "Guggenheim has downgraded Passage Bio (PASG.US) from a \"Buy\" rating to a \"Hold\" rating. This change reflects a revised outlook from the investment firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/71330038/guggenheim-downgrades-passage-bio-pasgus-to-hold-rating", "source_name": "Moomoo", "published_at": "2026-06-10T17:40:05", "published_display": "10 Jun 2026 17:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio (PASG) Downgraded to Neutral as Strategic Review Initiated", "summary": "Guggenheim analyst Debjit Chattopadhyay has downgraded Passage Bio (PASG) from \"Buy\" to \"Neutral\" and ceased coverage, citing uncertainties as the company begins a strategic review to enhance shareholder value, potentially through mergers or acquisitions. Passage Bio, a biotechno", "url": "https://www.gurufocus.com/news/8909636/passage-bio-pasg-downgraded-to-neutral-as-strategic-review-initiated", "source_name": "GuruFocus", "published_at": "2026-06-10T12:10:29", "published_display": "10 Jun 2026 12:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNZl9acG9NWk9ldHEwbkhUQUwwSjVQV0pycVVGald1cDM4ZDlxVGgwejhpTzc0VVdWc1U3R2xISkY3OWUtX1lBRWR2bFk5amxhN2VuZWtTYVRxcWsyUnN1SzM2WmN5QU55dEFzQjVjRUxfM2xhUUI0S241YXhPMFhYVVhSNVFaemV6SkM0dkludXp5d0J6NFE?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio to cut its workforce to the bone, laying off 75% of remaining employees", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPMGkwdEl1Yk9tckVqYkVKeUgwVzFra2hYc3BHV2EyeU5QTXFXbTY1UmlkZVBEQTUzSkt0NFdWSEUzSG5MT0tGQ29yS0U0cjZJekJRSEY2UzNzbzVnX0twekl5N241SnRNSERBa0FfSm1tRzYyRFVqU1c0dFNyNXQ3cmZnMS0td3NlRWxCM1pUX2ozalpwMk9ReG9ZQUhsNmlVM3dxeEozd2lZYUU?oc=5", "source_name": "The Business Journals", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio Shares Latest Interim Data from UpliFT-D Clinical Trial - AFTD", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTFB1U1BHcVJzYmlFOVJQcFRKU0lVTjZWMGxuRFNLeXJiMzZtWmZqTjVmeXdtME1ycHdWMEdPTzNoTzNoNEl2Yjd6cGtpZzRwNGR5N0ZvN3FzZDRGdG5fRWNMOW9tdHh2Q24zQ1ltSjU5YVRFX2wza3hHaDdBQURqZw?oc=5", "source_name": "The Association for Frontotemporal Degeneration", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Says", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/passage-bio-faces-tougher-fda-182044884.html", "source_name": "MT Newswires", "published_at": "2026-04-21T18:20:44+00:00", "published_display": "21 Apr 2026 18:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA wants a controlled trial even as Passage Bio posts biomarker gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNZHRMZkR0MjRESzVtODBOZ3QxUjlNYjRVbzVza2NsVmJkUklOcTBXT29xUHJwQ1ZkNHVBZEZPSVFJbVQ5S09fZGdoc2lqajVpRzQxSjFfWkxuelR5NDlBQW1BWTF4b1J1eklhWW9Za0J3WFROU0c1bGRFaEJyNzI4d0c5bUNIemlmX2RBd0t2MEhsNk5iUFp1aTNEd1dKc1E2VEViM2otbGtmcVkxV0pDR0hFbkN1NTVGVldDRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxNeWxEN3Excm1oajE3M2hKUVFPdTZ4YWQzSEVIbTRLWU5XZzFUM2U4dFVPTXIwUFpUQ2dYUEFNV1BVOHdBOW5kVUtDMUJFNjc5YlNDeXRrSEt2MnUyVEtkWmEwZHBYdUxialExdmFlblpyYk13ZmszTF9UaU4wN2pZS0ZKVUpUMFJsVXB6VWJDYmlMdWctNEd2bGhsQU43WlV5MF91YVQxUDAwaTR2UUJsbkNKdmh6RFRFNlM3aGp3V21jRThVTzZvRDlPOUVxOEZwYTNIb3l3U0Fva2F0d1JGNWhjNHpMbEZBV2Jvc0x2TFpVX3hsQ09oNm1lbTV1Zy1NdmFtVzBRRzBzZw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio reports biomarker improvements in FTD trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQVWhOVHVEUFplVVNVbUNMdmszX2ZrVUF4WXJiRzNtallXM2pqNF82djJBMXVUUXU0dlpUNFdQS3JpRzltN1lkNkgybVFqVFhRZWhheGZ6Ri1QSy0yU0lkLU5YRVVsYWpzRUJLUXBFX1pVQlozZ18xc1AtUklHd3k5NDctNUg0eUl1Y2wzMldOSDFQckpISjJWcGhidXIxQ0xxU2lsUGRkX0dKaGhvVi0wdHZ3?oc=5", "source_name": "Investing.com", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxNMVRFZDhZMWoyWTBaU2xhbXBjbzFUVUJ3SHdkZ0tWUkdrdVRVcUJoREFvNm9sUGVBZ1ZBTGtSeHctbE9oZGc3ZmFUU1dYc283a3lMby0tR3lTdmdzc0dSQ2NNSHRLeXJjZjBlbElnRE0tcVJidE9Idl9mRGxoU3plRHJSaThaMkY1Q0p1ZHMtTzNubmlXZTQtemxaQ3lXUXNrdUo0bzF2ZEp5amk3cHNkOGNQVnRYQUVrSFVJdXFmbkpRR29UQzVzOHgyXy1DYVJvcXlCbGwyeGJ3REUzOEJxeWI2bWozaUlydWltRHpiVW5DNF9JbTliUW80dU42UE5hc01jTkIzajFvVU14bjN5Vg?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Passage Bio (PASG)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE83cC1FZ0VId1U3VmRqbEhFa3BwVHk2bjhjeG5WeUFzWGlnbmhPUTVZdWdNT0JrUDktYXpRVEJKTDVYQzNQVE1WQWMxOEtabWJOT1BkOWZub0xtTnoycVI2NnBZYnJvLUlqSUJ0aA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2025-08-15T07:00:00+00:00", "published_display": "15 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Passage Bio\u2019s Dementia Gene Therapy Trial Expands Patient Pool", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPYkY1dmtYQkw0M2pCYWlKX3ljX1ppNU9FM3R4VktVMXFKc3huNHlaekZDSmdfTlNpSEZkeDZzdUt6RkdBbzNZNjBLOGNVVnFNN2k0OVBZTjdBV0xHVDl0dTJrX05TNDNhWnFObmplWDFhS3AzSFNDZ2x3N0FGa3BVb2lLVkZKcC1QdzRRS2hwclVTZzl3Q3dSLUlNdnlGU1VhWXZjTk9nYXIydFd3MHJRVGY0VnF1UjdjUTZQZm5FWDcyMXkwYjNN?oc=5", "source_name": "Inside Precision Medicine", "published_at": "2024-07-17T07:00:00+00:00", "published_display": "17 Jul 2024 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 50, "sentiment_summary": {"positive": 15, "negative": 7, "neutral": 28, "score": 53, "total": 50, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "deals", "primary_label": "Deals and strategy", "confidence": 72, "events": [{"event": "deals", "label": "Deals and strategy", "weight": 9.35, "count": 17}, {"event": "general", "label": "Market update", "weight": 9.15, "count": 16}, {"event": "earnings", "label": "Earnings", "weight": 6.05, "count": 13}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 4.57, "latest_week": "2026-07-10", "one_week_move": -2.4, "four_week_move": -21.3, "twelve_week_move": -60.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.553312, "market_dynamics_buy_signal": false, "relative_strength": -51.070899, "fair_value_gap": -65.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 43.0356, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.4% over one week, -21.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 59, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Deals and strategy", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 10}, {"label": "Stock Titan", "count": 8}, {"label": "Market source", "count": 6}, {"label": "AD HOC NEWS", "count": 2}, {"label": "The Business Journals", "count": 2}, {"label": "Moomoo", "count": 2}, {"label": "MT Newswires", "count": 2}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Deals and strategy", "count": 17}, {"label": "Market update", "count": 16}, {"label": "Earnings", "count": 13}, {"label": "Regulatory and legal", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Deals and strategy", "tone": "neutral", "text": "72/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.4% over one week, -21.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Passage Bio eyes gene therapy progress as Nasdaq-listed biotech develops CNS pipeline"}], "updated_at": "2026-07-16T13:30:40.528211+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}